Duchenne muscular dystrophy is the latest rare disease market to attract the attention of investors and big pharma. It may also be the launching pad for the next turbo-charged small-cap developer, as Sarepta Therapeutics Inc. demonstrated recently with its release of promising Phase IIB results.
Numerous assets addressing a variety of biological targets – early and late stage, partnered and unpartnered – are advancing through...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?